Overview
Citrobacter freundii is a Gram-negative, facultatively anaerobic, rod-shaped bacterium that occupies a dual role as both a normal member of the human gut microbiota and an opportunistic pathogen. Found in the gastrointestinal tract of an estimated 10-50% of healthy adults, C. freundii typically exists in a commensal relationship with its host. However, in immunocompromised, elderly, or hospitalized individuals, particularly those receiving antibiotic therapy, the organism can cause a variety of infections. It is also widely distributed in the environment, found in soil, water, and food.
Classification
C. freundii belongs to the phylum Pseudomonadota, class Gammaproteobacteria, order Enterobacterales, and family Enterobacteriaceae. The genus Citrobacter includes several species, with C. freundii and C. koseri being the most clinically relevant. A closely related species, Citrobacter rodentium, serves as an important murine model organism for studying attaching and effacing intestinal pathogenesis, providing insights that directly translate to understanding E. coli virulence mechanisms in humans, particularly enteropathogenic and enterohemorrhagic strains.
Key Characteristics
Like many members of the Enterobacteriaceae, C. freundii possesses a chromosomal AmpC beta-lactamase that provides intrinsic resistance to ampicillin and first-generation cephalosporins. Of growing concern is the organism's capacity to acquire additional resistance mechanisms, including extended-spectrum beta-lactamases (ESBLs) and carbapenemases, through horizontal gene transfer. Multidrug-resistant strains are increasingly reported in healthcare settings. The organism also produces citrate permease, allowing it to utilize citrate as a sole carbon source, a feature that distinguishes the genus and contributes to its metabolic versatility in diverse environments including the gut.
Health Significance
C. freundii primarily causes opportunistic infections in healthcare settings, including urinary tract infections, biliary tract infections, bacteremia, and neonatal meningitis. The clinical significance of this organism arises predominantly in patients who are hospitalized, immunocompromised, or have received broad-spectrum antibiotics that disrupt the normal gut microbiota. A healthy, diverse gut microbial community appears to provide effective colonization resistance against Citrobacter overgrowth. Research using mouse models with Citrobacter rodentium has demonstrated that commensal gut bacteria, including Bacteroides species, can provide competitive exclusion against pathogenic Citrobacter colonization. The emergence of carbapenem-resistant strains is a particular concern in nosocomial settings. C. freundii may be detected on comprehensive gut microbiome testing panels, where its presence at low levels is generally considered normal, though elevated abundances could indicate dysbiosis.